Abstract
Background: During the COVID-19 pandemic, various public health and social measures (PHSM) were implemented with the primary objective of curtailing the transmission of SARS-CoV-2. This review aims to synthesise existing evidence on the effectiveness of medical facemasks and/or respirators (FFP2/KN95/N95) in reducing SARS-CoV-2 transmission/infection in community settings. Methods: A scoping literature review adhering to PRISMA was performed. All relevant study designs within community settings, excluding modelling studies, published between January 2000 and January 2023 and indexed in Medline and Embase were included with no geographical limitation. Studies not specifying facemask/respirator type or not presenting isolated outcomes for specific facemask/respirator types were excluded. Results: Of the 10,185 studies identified, two randomised controlled trials (RCT) and two case-control studies met all inclusion criteria. The largest RCT identified an adjusted prevalence ratio of 0.89 (95%CI: 0.78-1.00) for medical vs. cloth masks. In a smaller RCT, the between-group difference favoured the mask vs no mask group (- 0.3 percentage points; 95%CI: -1.2 to 0.4). Within one case-control study, N95/KN95 respirators (aOR 0.17; 95%CI: 0.05-0.64) or medical masks (aOR 0.34; 95%CI: 0.13-0.90) were associated with statistically significant lower adjusted odds of a positive test result compared to no facemask use. A second case-control study associated medical mask use with reduced COVID-19 risk in unadjusted models (OR 0.25; 95% CI: 0.12-0.53) but this effect was not independently associated with infection in multivariable models (aOR 0.61; 95%CI: 0.25-1.49). Conclusions: Limited published evidence exists on the effectiveness of medical facemask use in community settings. Medical masks and respirators (compared to cloth masks) may reduce SARS-CoV-2 transmission, but interpretation requires caution. Mask use in community settings was rarely implemented in isolation to other PHSMs so deciphering whether the effect is solely because of mask-wearing or a combined effect is extremely challenging necessitating additional studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This report was commissioned by the European Centre for Disease Prevention and Control (ECDC), to the PREP-EU Consortium under specific contract ECD.14638 within framework contract ECDC/2019/001, Lot 1B.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data sharing is not applicable to this article as no new data were created or analysed in this study.
